Share Price and Basic Stock Data
Last Updated: February 10, 2026, 8:43 pm
| PEG Ratio | 5.21 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Fortis Healthcare Ltd operates in the Hospitals & Medical Services industry and has reported a market capitalization of ₹63,266 Cr with a current share price of ₹838. The company has demonstrated a positive revenue trajectory, with sales increasing from ₹5,718 Cr in FY 2022 to ₹6,298 Cr in FY 2023, and further projected to rise to ₹7,783 Cr in FY 2025. The quarterly sales figures reflect this growth, with sales standing at ₹1,607 Cr in Sep 2022 and climbing to ₹1,770 Cr by Sep 2023. The company’s operating profit margin (OPM) has also shown improvement, rising from 19% in FY 2022 to a projected 20% in FY 2025. The increase in revenue is indicative of Fortis’s ability to capture market share amid rising healthcare demand, as evidenced by its consistent quarterly revenue growth. Notably, the company reported net profits of ₹1,038 Cr for the TTM period, showcasing its robust operational performance.
Profitability and Efficiency Metrics
Fortis Healthcare’s profitability metrics indicate a strong performance. The net profit for FY 2023 stood at ₹633 Cr, which is expected to rise to ₹809 Cr in FY 2025. This growth is further supported by the company’s net profit margin, which has improved from 9.70% in FY 2023 to 10.25% in FY 2025. The operating profit has also risen, reflecting increased operational efficiency, with an OPM of 20% projected for FY 2025. Additionally, the return on equity (ROE) is reported at 10.1%, while the return on capital employed (ROCE) stands at 12%, both of which are favorable compared to typical industry averages. Fortis also maintains a cash conversion cycle (CCC) of -101 days, indicating that the company efficiently manages its working capital. However, the interest coverage ratio (ICR) of 8.97x suggests a relatively high debt burden, which could pose risks if not managed prudently.
Balance Sheet Strength and Financial Ratios
Fortis Healthcare demonstrates a balanced approach to its financial health, with total assets increasing from ₹11,516 Cr in FY 2022 to ₹13,377 Cr in FY 2025. The company reported reserves of ₹8,674 Cr, reflecting a robust capital base. Borrowings have risen to ₹3,195 Cr, which, while higher, remains manageable given the company’s strong operational cash flows. The debt-to-equity ratio stands at 0.24, indicating a conservative leverage position compared to industry norms. The price-to-book value (P/BV) ratio of 5.91x suggests that the stock is trading at a premium, reflecting investor confidence in future growth prospects. Moreover, the current ratio of 0.91 and quick ratio of 0.84 indicate that Fortis may face liquidity challenges in short-term obligations, which is a potential area of concern. The company’s financial ratios, including a return on net worth of 8.68%, reflect a solid performance relative to its peers.
Shareholding Pattern and Investor Confidence
Fortis Healthcare’s shareholding structure reveals a diverse base of investors. Promoters hold 31.17% of the shares, while foreign institutional investors (FIIs) and domestic institutional investors (DIIs) account for 27.90% and 29.14%, respectively. Public shareholding stands at 11.79%, indicating a healthy distribution among institutional and retail investors. The number of shareholders has grown to 2,20,766, underscoring increasing investor interest. However, FII participation has seen a decline from 31.22% in March 2023 to 27.90% by September 2025, which may reflect concerns about valuation or market conditions. The steady DII holdings indicate confidence among domestic investors, which is crucial for price stability. Overall, the shareholding pattern illustrates a balanced mix of institutional and retail investors, which is generally positive for market sentiment.
Outlook, Risks, and Final Insight
Looking ahead, Fortis Healthcare is well-positioned to capitalize on the growing healthcare market in India, supported by its robust revenue growth and profitability metrics. Strengths include a solid operational performance with improving margins, high institutional ownership suggesting confidence, and a manageable debt level. However, risks include potential liquidity challenges reflected in current ratios, reliance on continued revenue growth to service increasing borrowings, and the decline in FII holdings which may affect stock price stability. The company must navigate these risks while maintaining its growth trajectory. In scenarios where revenue growth sustains, Fortis could further enhance profitability and shareholder value. Conversely, if market conditions lead to reduced demand or operational inefficiencies, the company may face challenges in maintaining its current performance levels. Strategic focus on cost management and enhancing service offerings will be crucial for sustaining investor confidence and achieving long-term success.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| NG Industries Ltd | 48.2 Cr. | 144 | 187/120 | 117 | 2.43 % | 23.6 % | 20.7 % | 10.0 | |
| Global Longlife Hospital and Research Ltd | 13.5 Cr. | 12.8 | 33.0/12.8 | 24.3 | 0.00 % | 13.7 % | 17.7 % | 10.0 | |
| Gian Lifecare Ltd | 10.2 Cr. | 9.89 | 20.5/7.08 | 18.7 | 0.00 % | 3.00 % | 0.81 % | 10.0 | |
| Fortis Malar Hospitals Ltd | 105 Cr. | 55.8 | 98.7/52.2 | 23.0 | 18.3 | 0.00 % | 0.83 % | 0.56 % | 10.0 |
| Family Care Hospitals Ltd | 19.3 Cr. | 3.58 | 6.12/3.28 | 1.51 | 0.00 % | 79.2 % | 85.5 % | 10.0 | |
| Industry Average | 25,758.00 Cr | 691.23 | 95.15 | 92.86 | 0.34% | 15.48% | 14.81% | 9.04 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,607 | 1,560 | 1,643 | 1,657 | 1,770 | 1,680 | 1,786 | 1,859 | 1,988 | 1,928 | 2,007 | 2,167 | 2,331 |
| Expenses | 1,304 | 1,283 | 1,372 | 1,386 | 1,440 | 1,396 | 1,405 | 1,516 | 1,554 | 1,553 | 1,572 | 1,676 | 1,775 |
| Operating Profit | 303 | 276 | 271 | 272 | 330 | 284 | 381 | 343 | 435 | 375 | 435 | 491 | 556 |
| OPM % | 19% | 18% | 16% | 16% | 19% | 17% | 21% | 18% | 22% | 19% | 22% | 23% | 24% |
| Other Income | 75 | 26 | 26 | 10 | 18 | 19 | 17 | 14 | -42 | 47 | -29 | 31 | 50 |
| Interest | 33 | 33 | 32 | 31 | 32 | 33 | 35 | 35 | 36 | 45 | 68 | 70 | 75 |
| Depreciation | 77 | 83 | 82 | 79 | 84 | 87 | 92 | 91 | 95 | 97 | 102 | 101 | 106 |
| Profit before tax | 268 | 186 | 183 | 171 | 233 | 183 | 271 | 230 | 261 | 279 | 237 | 351 | 425 |
| Tax % | 19% | 24% | 25% | 27% | 21% | 27% | 25% | 24% | 26% | 9% | 21% | 24% | 23% |
| Net Profit | 218 | 142 | 138 | 124 | 184 | 134 | 203 | 174 | 193 | 254 | 188 | 267 | 329 |
| EPS in Rs | 2.71 | 1.72 | 1.76 | 1.48 | 2.30 | 1.78 | 2.37 | 2.20 | 2.34 | 3.28 | 2.44 | 3.45 | 4.26 |
Last Updated: January 12, 2026, 9:16 am
Below is a detailed analysis of the quarterly data for Fortis Healthcare Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 2,331.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,167.00 Cr. (Jun 2025) to 2,331.00 Cr., marking an increase of 164.00 Cr..
- For Expenses, as of Sep 2025, the value is 1,775.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,676.00 Cr. (Jun 2025) to 1,775.00 Cr., marking an increase of 99.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 556.00 Cr.. The value appears strong and on an upward trend. It has increased from 491.00 Cr. (Jun 2025) to 556.00 Cr., marking an increase of 65.00 Cr..
- For OPM %, as of Sep 2025, the value is 24.00%. The value appears strong and on an upward trend. It has increased from 23.00% (Jun 2025) to 24.00%, marking an increase of 1.00%.
- For Other Income, as of Sep 2025, the value is 50.00 Cr.. The value appears strong and on an upward trend. It has increased from 31.00 Cr. (Jun 2025) to 50.00 Cr., marking an increase of 19.00 Cr..
- For Interest, as of Sep 2025, the value is 75.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 70.00 Cr. (Jun 2025) to 75.00 Cr., marking an increase of 5.00 Cr..
- For Depreciation, as of Sep 2025, the value is 106.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 101.00 Cr. (Jun 2025) to 106.00 Cr., marking an increase of 5.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 425.00 Cr.. The value appears strong and on an upward trend. It has increased from 351.00 Cr. (Jun 2025) to 425.00 Cr., marking an increase of 74.00 Cr..
- For Tax %, as of Sep 2025, the value is 23.00%. The value appears to be improving (decreasing) as expected. It has decreased from 24.00% (Jun 2025) to 23.00%, marking a decrease of 1.00%.
- For Net Profit, as of Sep 2025, the value is 329.00 Cr.. The value appears strong and on an upward trend. It has increased from 267.00 Cr. (Jun 2025) to 329.00 Cr., marking an increase of 62.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 4.26. The value appears strong and on an upward trend. It has increased from 3.45 (Jun 2025) to 4.26, marking an increase of 0.81.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:22 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,492 | 3,966 | 4,199 | 4,574 | 4,561 | 4,469 | 4,632 | 4,030 | 5,718 | 6,298 | 6,893 | 7,783 | 8,434 |
| Expenses | 3,430 | 3,857 | 4,106 | 4,220 | 4,287 | 4,238 | 4,022 | 3,626 | 4,649 | 5,196 | 5,625 | 6,195 | 6,576 |
| Operating Profit | 62 | 109 | 92 | 354 | 274 | 231 | 610 | 404 | 1,069 | 1,101 | 1,268 | 1,588 | 1,858 |
| OPM % | 2% | 3% | 2% | 8% | 6% | 5% | 13% | 10% | 19% | 17% | 18% | 20% | 22% |
| Other Income | 152 | 92 | 299 | 649 | -689 | 228 | 126 | 95 | 367 | 157 | 64 | -11 | 98 |
| Interest | 250 | 152 | 133 | 229 | 258 | 337 | 205 | 166 | 147 | 129 | 131 | 184 | 257 |
| Depreciation | 183 | 235 | 225 | 222 | 239 | 233 | 292 | 291 | 301 | 316 | 342 | 386 | 407 |
| Profit before tax | -219 | -185 | 34 | 552 | -912 | -110 | 239 | 43 | 988 | 814 | 858 | 1,007 | 1,292 |
| Tax % | 5% | 2% | -24% | 13% | 2% | 103% | 62% | 230% | 20% | 22% | 25% | 20% | |
| Net Profit | -218 | -130 | 42 | 479 | -934 | -224 | 91 | -56 | 790 | 633 | 645 | 809 | 1,038 |
| EPS in Rs | -4.73 | -3.10 | 0.40 | 8.14 | -19.46 | -3.96 | 0.77 | -1.45 | 7.35 | 7.80 | 7.93 | 10.26 | 13.43 |
| Dividend Payout % | -0% | -1% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 13% | 13% | 10% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 40.37% | 132.31% | 1040.48% | -294.99% | 76.02% | 140.62% | -161.54% | 1510.71% | -19.87% | 1.90% | 25.43% |
| Change in YoY Net Profit Growth (%) | 0.00% | 91.94% | 908.17% | -1335.47% | 371.01% | 64.61% | -302.16% | 1672.25% | -1530.59% | 21.77% | 23.53% |
Fortis Healthcare Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 11% |
| 3 Years: | 11% |
| TTM: | 14% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 23% |
| 5 Years: | 70% |
| 3 Years: | 31% |
| TTM: | 43% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 20% |
| 5 Years: | 48% |
| 3 Years: | 49% |
| 1 Year: | 69% |
| Return on Equity | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 6% |
| 3 Years: | 9% |
| Last Year: | 10% |
Last Updated: September 5, 2025, 4:15 am
Balance Sheet
Last Updated: December 4, 2025, 1:15 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 463 | 463 | 463 | 518 | 519 | 755 | 755 | 755 | 755 | 755 | 755 | 755 | 755 |
| Reserves | 3,820 | 3,585 | 3,998 | 4,626 | 3,543 | 5,846 | 5,906 | 5,365 | 5,423 | 6,487 | 6,908 | 8,162 | 8,674 |
| Borrowings | 2,550 | 1,784 | 1,513 | 2,217 | 1,962 | 2,010 | 1,594 | 1,531 | 1,255 | 926 | 1,155 | 2,475 | 3,195 |
| Other Liabilities | 1,018 | 1,760 | 1,257 | 2,227 | 2,455 | 2,875 | 2,781 | 3,216 | 4,082 | 3,921 | 4,153 | 1,985 | 2,389 |
| Total Liabilities | 7,851 | 7,592 | 7,232 | 9,588 | 8,479 | 11,486 | 11,036 | 10,866 | 11,516 | 12,089 | 12,971 | 13,377 | 15,013 |
| Fixed Assets | 4,147 | 4,218 | 3,642 | 5,419 | 4,992 | 8,477 | 8,802 | 8,799 | 9,416 | 9,426 | 9,874 | 10,424 | 11,703 |
| CWIP | 147 | 228 | 226 | 268 | 226 | 450 | 204 | 165 | 193 | 228 | 542 | 407 | 306 |
| Investments | 1,817 | 1,464 | 1,452 | 1,878 | 1,732 | 270 | 175 | 186 | 104 | 210 | 230 | 169 | 220 |
| Other Assets | 1,739 | 1,682 | 1,913 | 2,023 | 1,529 | 2,290 | 1,856 | 1,716 | 1,803 | 2,225 | 2,326 | 2,378 | 2,784 |
| Total Assets | 7,851 | 7,592 | 7,232 | 9,588 | 8,479 | 11,486 | 11,036 | 10,866 | 11,516 | 12,089 | 12,971 | 13,377 | 15,013 |
Below is a detailed analysis of the balance sheet data for Fortis Healthcare Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 755.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 755.00 Cr..
- For Reserves, as of Sep 2025, the value is 8,674.00 Cr.. The value appears strong and on an upward trend. It has increased from 8,162.00 Cr. (Mar 2025) to 8,674.00 Cr., marking an increase of 512.00 Cr..
- For Borrowings, as of Sep 2025, the value is 3,195.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 2,475.00 Cr. (Mar 2025) to 3,195.00 Cr., marking an increase of 720.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 2,389.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,985.00 Cr. (Mar 2025) to 2,389.00 Cr., marking an increase of 404.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 15,013.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 13,377.00 Cr. (Mar 2025) to 15,013.00 Cr., marking an increase of 1,636.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 11,703.00 Cr.. The value appears strong and on an upward trend. It has increased from 10,424.00 Cr. (Mar 2025) to 11,703.00 Cr., marking an increase of 1,279.00 Cr..
- For CWIP, as of Sep 2025, the value is 306.00 Cr.. The value appears to be declining and may need further review. It has decreased from 407.00 Cr. (Mar 2025) to 306.00 Cr., marking a decrease of 101.00 Cr..
- For Investments, as of Sep 2025, the value is 220.00 Cr.. The value appears strong and on an upward trend. It has increased from 169.00 Cr. (Mar 2025) to 220.00 Cr., marking an increase of 51.00 Cr..
- For Other Assets, as of Sep 2025, the value is 2,784.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,378.00 Cr. (Mar 2025) to 2,784.00 Cr., marking an increase of 406.00 Cr..
- For Total Assets, as of Sep 2025, the value is 15,013.00 Cr.. The value appears strong and on an upward trend. It has increased from 13,377.00 Cr. (Mar 2025) to 15,013.00 Cr., marking an increase of 1,636.00 Cr..
Notably, the Reserves (8,674.00 Cr.) exceed the Borrowings (3,195.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 60.00 | 108.00 | 91.00 | 352.00 | 273.00 | 229.00 | 609.00 | 403.00 | 0.00 | -925.00 | 0.00 | -1.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 46 | 38 | 39 | 38 | 38 | 44 | 36 | 41 | 33 | 34 | 33 | 37 |
| Inventory Days | 26 | 25 | 23 | 23 | 24 | 22 | 30 | 29 | 33 | 31 | 24 | 23 |
| Days Payable | 200 | 207 | 218 | 215 | 279 | 296 | 226 | 205 | 178 | 179 | 164 | 161 |
| Cash Conversion Cycle | -128 | -144 | -156 | -155 | -217 | -230 | -161 | -135 | -112 | -115 | -107 | -101 |
| Working Capital Days | -19 | -71 | -69 | -87 | -113 | -234 | -150 | -56 | -35 | -22 | -124 | -30 |
| ROCE % | 0% | -0% | 3% | 11% | 3% | 6% | 4% | 2% | 10% | 10% | 10% | 12% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| HDFC Mid Cap Fund | 27,834,044 | 2.66 | 2460.53 | N/A | N/A | N/A |
| Kotak Midcap Fund | 24,724,343 | 3.6 | 2185.63 | N/A | N/A | N/A |
| Nippon India Growth Mid Cap Fund | 13,542,021 | 2.84 | 1197.11 | N/A | N/A | N/A |
| Axis Midcap Fund | 13,060,764 | 3.64 | 1154.57 | 12,427,065 | 2026-01-26 05:00:11 | 5.1% |
| HDFC Small Cap Fund | 9,440,132 | 2.21 | 834.51 | 9,973,132 | 2025-12-15 02:41:06 | -5.34% |
| DSP Mid Cap Fund | 5,671,639 | 2.56 | 501.37 | 5,152,245 | 2026-01-25 02:09:10 | 10.08% |
| Aditya Birla Sun Life ELSS Tax Saver Fund | 4,912,331 | 2.82 | 434.25 | 8,360,144 | 2025-12-07 02:17:25 | -41.24% |
| HDFC Large and Mid Cap Fund | 4,733,349 | 1.44 | 418.43 | N/A | N/A | N/A |
| Kotak Large & Midcap Fund | 4,300,000 | 1.27 | 380.12 | 4,200,000 | 2026-01-25 02:09:10 | 2.38% |
| Kotak Aggressive Hybrid Fund | 2,988,167 | 3.1 | 264.15 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 10.26 | 7.93 | 7.80 | 7.35 | -1.45 |
| Diluted EPS (Rs.) | 10.26 | 7.93 | 7.80 | 7.35 | -1.45 |
| Cash EPS (Rs.) | 15.68 | 12.96 | 12.28 | 14.13 | 2.48 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 118.11 | 113.33 | 107.30 | 92.83 | 88.98 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 118.11 | 113.33 | 107.30 | 92.83 | 88.98 |
| Revenue From Operations / Share (Rs.) | 103.09 | 91.30 | 83.42 | 75.73 | 53.38 |
| PBDIT / Share (Rs.) | 21.92 | 17.30 | 15.40 | 14.52 | 5.97 |
| PBIT / Share (Rs.) | 16.81 | 12.76 | 11.22 | 10.54 | 2.12 |
| PBT / Share (Rs.) | 13.19 | 11.24 | 10.49 | 12.76 | -0.05 |
| Net Profit / Share (Rs.) | 10.57 | 8.42 | 8.10 | 10.14 | -1.37 |
| NP After MI And SOA / Share (Rs.) | 10.26 | 7.93 | 7.80 | 7.35 | -1.45 |
| PBDIT Margin (%) | 21.26 | 18.94 | 18.46 | 19.17 | 11.19 |
| PBIT Margin (%) | 16.30 | 13.97 | 13.45 | 13.91 | 3.98 |
| PBT Margin (%) | 12.79 | 12.30 | 12.57 | 16.85 | -0.10 |
| Net Profit Margin (%) | 10.25 | 9.22 | 9.70 | 13.39 | -2.57 |
| NP After MI And SOA Margin (%) | 9.94 | 8.68 | 9.34 | 9.70 | -2.72 |
| Return on Networth / Equity (%) | 8.68 | 7.81 | 8.12 | 8.98 | -1.79 |
| Return on Capital Employeed (%) | 10.50 | 9.52 | 7.69 | 7.49 | 1.61 |
| Return On Assets (%) | 5.65 | 4.50 | 4.73 | 4.67 | -0.98 |
| Long Term Debt / Equity (X) | 0.23 | 0.09 | 0.07 | 0.12 | 0.15 |
| Total Debt / Equity (X) | 0.24 | 0.11 | 0.09 | 0.15 | 0.18 |
| Asset Turnover Ratio (%) | 0.57 | 0.53 | 0.09 | 0.07 | 0.05 |
| Current Ratio (X) | 0.91 | 0.44 | 0.98 | 0.89 | 0.84 |
| Quick Ratio (X) | 0.84 | 0.41 | 0.90 | 0.79 | 0.77 |
| Inventory Turnover Ratio (X) | 69.89 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend Payout Ratio (NP) (%) | 9.99 | 12.60 | 0.00 | 0.00 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 6.67 | 8.01 | 0.00 | 0.00 | 0.00 |
| Earning Retention Ratio (%) | 90.01 | 87.40 | 0.00 | 0.00 | 0.00 |
| Cash Earning Retention Ratio (%) | 93.33 | 91.99 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 8.97 | 9.97 | 9.01 | 7.47 | 2.72 |
| Interest Coverage Ratio (Post Tax) (X) | 5.81 | 5.73 | 5.16 | 4.07 | 0.36 |
| Enterprise Value (Cr.) | 54674.02 | 32853.83 | 20823.69 | 23306.97 | 16352.45 |
| EV / Net Operating Revenue (X) | 7.03 | 4.77 | 3.31 | 4.08 | 4.06 |
| EV / EBITDA (X) | 33.04 | 25.16 | 17.90 | 21.26 | 36.26 |
| MarketCap / Net Operating Revenue (X) | 6.78 | 4.60 | 3.12 | 3.83 | 3.73 |
| Retention Ratios (%) | 90.00 | 87.39 | 0.00 | 0.00 | 0.00 |
| Price / BV (X) | 5.91 | 4.14 | 2.71 | 3.55 | 2.45 |
| Price / Net Operating Revenue (X) | 6.78 | 4.60 | 3.12 | 3.83 | 3.73 |
| EarningsYield | 0.01 | 0.01 | 0.02 | 0.02 | -0.01 |
After reviewing the key financial ratios for Fortis Healthcare Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 10.26. This value is within the healthy range. It has increased from 7.93 (Mar 24) to 10.26, marking an increase of 2.33.
- For Diluted EPS (Rs.), as of Mar 25, the value is 10.26. This value is within the healthy range. It has increased from 7.93 (Mar 24) to 10.26, marking an increase of 2.33.
- For Cash EPS (Rs.), as of Mar 25, the value is 15.68. This value is within the healthy range. It has increased from 12.96 (Mar 24) to 15.68, marking an increase of 2.72.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 118.11. It has increased from 113.33 (Mar 24) to 118.11, marking an increase of 4.78.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 118.11. It has increased from 113.33 (Mar 24) to 118.11, marking an increase of 4.78.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 103.09. It has increased from 91.30 (Mar 24) to 103.09, marking an increase of 11.79.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 21.92. This value is within the healthy range. It has increased from 17.30 (Mar 24) to 21.92, marking an increase of 4.62.
- For PBIT / Share (Rs.), as of Mar 25, the value is 16.81. This value is within the healthy range. It has increased from 12.76 (Mar 24) to 16.81, marking an increase of 4.05.
- For PBT / Share (Rs.), as of Mar 25, the value is 13.19. This value is within the healthy range. It has increased from 11.24 (Mar 24) to 13.19, marking an increase of 1.95.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 10.57. This value is within the healthy range. It has increased from 8.42 (Mar 24) to 10.57, marking an increase of 2.15.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 10.26. This value is within the healthy range. It has increased from 7.93 (Mar 24) to 10.26, marking an increase of 2.33.
- For PBDIT Margin (%), as of Mar 25, the value is 21.26. This value is within the healthy range. It has increased from 18.94 (Mar 24) to 21.26, marking an increase of 2.32.
- For PBIT Margin (%), as of Mar 25, the value is 16.30. This value is within the healthy range. It has increased from 13.97 (Mar 24) to 16.30, marking an increase of 2.33.
- For PBT Margin (%), as of Mar 25, the value is 12.79. This value is within the healthy range. It has increased from 12.30 (Mar 24) to 12.79, marking an increase of 0.49.
- For Net Profit Margin (%), as of Mar 25, the value is 10.25. This value exceeds the healthy maximum of 10. It has increased from 9.22 (Mar 24) to 10.25, marking an increase of 1.03.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 9.94. This value is within the healthy range. It has increased from 8.68 (Mar 24) to 9.94, marking an increase of 1.26.
- For Return on Networth / Equity (%), as of Mar 25, the value is 8.68. This value is below the healthy minimum of 15. It has increased from 7.81 (Mar 24) to 8.68, marking an increase of 0.87.
- For Return on Capital Employeed (%), as of Mar 25, the value is 10.50. This value is within the healthy range. It has increased from 9.52 (Mar 24) to 10.50, marking an increase of 0.98.
- For Return On Assets (%), as of Mar 25, the value is 5.65. This value is within the healthy range. It has increased from 4.50 (Mar 24) to 5.65, marking an increase of 1.15.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.23. This value is within the healthy range. It has increased from 0.09 (Mar 24) to 0.23, marking an increase of 0.14.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.24. This value is within the healthy range. It has increased from 0.11 (Mar 24) to 0.24, marking an increase of 0.13.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.57. It has increased from 0.53 (Mar 24) to 0.57, marking an increase of 0.04.
- For Current Ratio (X), as of Mar 25, the value is 0.91. This value is below the healthy minimum of 1.5. It has increased from 0.44 (Mar 24) to 0.91, marking an increase of 0.47.
- For Quick Ratio (X), as of Mar 25, the value is 0.84. This value is below the healthy minimum of 1. It has increased from 0.41 (Mar 24) to 0.84, marking an increase of 0.43.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 69.89. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 69.89, marking an increase of 69.89.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 9.99. This value is below the healthy minimum of 20. It has decreased from 12.60 (Mar 24) to 9.99, marking a decrease of 2.61.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 6.67. This value is below the healthy minimum of 20. It has decreased from 8.01 (Mar 24) to 6.67, marking a decrease of 1.34.
- For Earning Retention Ratio (%), as of Mar 25, the value is 90.01. This value exceeds the healthy maximum of 70. It has increased from 87.40 (Mar 24) to 90.01, marking an increase of 2.61.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 93.33. This value exceeds the healthy maximum of 70. It has increased from 91.99 (Mar 24) to 93.33, marking an increase of 1.34.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 8.97. This value is within the healthy range. It has decreased from 9.97 (Mar 24) to 8.97, marking a decrease of 1.00.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 5.81. This value is within the healthy range. It has increased from 5.73 (Mar 24) to 5.81, marking an increase of 0.08.
- For Enterprise Value (Cr.), as of Mar 25, the value is 54,674.02. It has increased from 32,853.83 (Mar 24) to 54,674.02, marking an increase of 21,820.19.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 7.03. This value exceeds the healthy maximum of 3. It has increased from 4.77 (Mar 24) to 7.03, marking an increase of 2.26.
- For EV / EBITDA (X), as of Mar 25, the value is 33.04. This value exceeds the healthy maximum of 15. It has increased from 25.16 (Mar 24) to 33.04, marking an increase of 7.88.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 6.78. This value exceeds the healthy maximum of 3. It has increased from 4.60 (Mar 24) to 6.78, marking an increase of 2.18.
- For Retention Ratios (%), as of Mar 25, the value is 90.00. This value exceeds the healthy maximum of 70. It has increased from 87.39 (Mar 24) to 90.00, marking an increase of 2.61.
- For Price / BV (X), as of Mar 25, the value is 5.91. This value exceeds the healthy maximum of 3. It has increased from 4.14 (Mar 24) to 5.91, marking an increase of 1.77.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 6.78. This value exceeds the healthy maximum of 3. It has increased from 4.60 (Mar 24) to 6.78, marking an increase of 2.18.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Fortis Healthcare Ltd:
- Net Profit Margin: 10.25%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 10.5% (Industry Average ROCE: 15.48%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 8.68% (Industry Average ROE: 14.81%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 5.81
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.84
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 66.8 (Industry average Stock P/E: 95.15)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.24
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 10.25%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Hospitals & Medical Services | Fortis Hospital, Sector 62, Phase - VIII, Mohali Punjab 160062 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Ashutosh Raghuvanshi | Managing Director & CEO |
| Ms. Suvalaxmi Chakraborty | Independent Director |
| Mr. Indrajit Banerjee | Independent Director |
| Ms. Shailaja Chandra | Independent Director |
| Mr. Tomo Nagahiro | Non Executive Director |
| Mr. Dilip Kadambi | Non Executive Director |
| Mr. Lim Tsin Lin | Non Executive Director |
| Mr. Mehmet Ali Aydinlar | Non Executive Director |
| Dr. Prem Kumar Nair | Non Executive Director |
| Mr. Ashok Pandit | Non Executive Director |
| Mr. Leo Puri | Chairman & Ind.Director |
FAQ
What is the intrinsic value of Fortis Healthcare Ltd?
Fortis Healthcare Ltd's intrinsic value (as of 11 February 2026) is ₹761.96 which is 14.58% lower the current market price of ₹892.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹67,327 Cr. market cap, FY2025-2026 high/low of ₹1,105/521, reserves of ₹8,674 Cr, and liabilities of ₹15,013 Cr.
What is the Market Cap of Fortis Healthcare Ltd?
The Market Cap of Fortis Healthcare Ltd is 67,327 Cr..
What is the current Stock Price of Fortis Healthcare Ltd as on 11 February 2026?
The current stock price of Fortis Healthcare Ltd as on 11 February 2026 is ₹892.
What is the High / Low of Fortis Healthcare Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Fortis Healthcare Ltd stocks is ₹1,105/521.
What is the Stock P/E of Fortis Healthcare Ltd?
The Stock P/E of Fortis Healthcare Ltd is 66.8.
What is the Book Value of Fortis Healthcare Ltd?
The Book Value of Fortis Healthcare Ltd is 125.
What is the Dividend Yield of Fortis Healthcare Ltd?
The Dividend Yield of Fortis Healthcare Ltd is 0.11 %.
What is the ROCE of Fortis Healthcare Ltd?
The ROCE of Fortis Healthcare Ltd is 12.0 %.
What is the ROE of Fortis Healthcare Ltd?
The ROE of Fortis Healthcare Ltd is 10.1 %.
What is the Face Value of Fortis Healthcare Ltd?
The Face Value of Fortis Healthcare Ltd is 10.0.